WHAT IS CLAIMED IS:

1. A pharmaceutical formulation comprising: (i) an antibody that binds specifically to human angiopoietin 2 (human Ang-2); (ii) a buffer at pH of 6.0 ± 0.3; (iii) a non-ionic detergent; and (iv) a stabilizer.

2. The pharmaceutical formulation of claim 1, wherein the antibody comprises an HCDR1 of SEQ ID NO: 4, an HCDR2 of SEQ ID NO: 6, an HCDR3 of SEQ ID NO: 8, an LCDR1 of SEQ ID NO: 12, an LCDR2 of SEQ ID NO: 14, and an LCDR3 of SEQ ID NO: 16.

3. The pharmaceutical formulation of any one of claims 1 and 2, wherein the antibody comprises a HCVD of SEQ ID NO: 18 and an LCVD of SEQ ID NO: 20.

4. The pharmaceutical formulation of any one of claims 1-3, wherein

(a) over 96% of the antibodies have a molecular weight of 151 kDa ± 1 kDa;

(b) at least 53% of the antibodies have an isoelectric point of about 8.13 ± 0.01; and

(c) from about 90% to about 92% of the antibodies are fucosylated.

5. The pharmaceutical formulation of any one of claims 1-4, wherein the antibody concentration is about 25 mg/mL ± 0.375 mg/mL, or about 50 mg/mL ± 7.5 mg/mL.

6. The pharmaceutical formulation of any one of claims 1-4, wherein the buffer is histidine.

7. The pharmaceutical formulation of claim 6, wherein the histidine concentration is 10 mM ± 1.5 mM.

8. The pharmaceutical formulation of any one of claims 1-7, wherein the non-ionic detergent is polysorbate 20.

9. The pharmaceutical formulation of claim 8, wherein the polysorbate 20 concentration is about 0.2% w/v ± 0.03%.

10. The pharmaceutical formulation of any one of claims 1-9, wherein the stabilizer is sucrose.

11. The pharmaceutical formulation of claim 10, wherein the sucrose concentration is about 10% ± 1.5% (w/v).

12. The pharmaceutical formulation of any one of claims 1-11, wherein the antibody concentration is 25 mg/mL ± 3.75 mg/mL, the buffer is 10mM ± 1.5mM histidine, pH 6 ± 0.3, the non-ionic detergent is 0.2% w/v ± 0.03%, and the stabilizer is 10% w/v ± 1.5% sucrose.

13. The pharmaceutical formulation of any one of claims 1-11, wherein the antibody concentration is 50 mg/mL ± 7.5 mg/mL, the buffer is 10mM ± 1.5mM histidine, pH 6 ± 0.3, the non-ionic detergent is 0.2% w/v ± 0.03%, and the stabilizer is 10% w/v ± 1.5% sucrose..

14. The pharmaceutical formulation of any one of claims 1-13, wherein at least 93% of the antibody has native conformation after 28 days at 45°C.

15. The pharmaceutical formulation of any one of claims 1-14, wherein at least 32% of the antibody is the main charge variant of the antibody after 28 days at 45°C.

16. The pharmaceutical formulation of any one of claims 1-15, wherein at least 97% of the antibody has native conformation after 28 days at 25°C.

17. The pharmaceutical formulation of any one of claims 1-16, wherein at least 53% of the antibody is the main charge variant of the antibody after 28 days at 25°C.

18. The pharmaceutical formulation of any one of claims 1-17, wherein at least 96% of the antibody has native conformation after 28 days at 37°C.

19. The pharmaceutical formulation of any one of claims 1-18, wherein at least 45% of the antibody is the main charge variant of the antibody after 28 days at 37°C.

20. The pharmaceutical formulation of any one of claims 1-19, wherein at least 97% of the antibody has native conformation after six months at 5°C.

21. The pharmaceutical formulation of any one of claims 1-20, wherein at least 55% of the antibody is the main charge variant of the antibody after six months at 5°C.

22. The pharmaceutical formulation of any one of claims 1-21, wherein the percent relative potency of the antibody after six months at 5°C is at least 100% of the potency of the antibody prior to storage.

23. The pharmaceutical formulation of any one of claims 1-22, wherein at least 97% of the antibody has native conformation after six months at -80°C.

24. The pharmaceutical formulation of any one of claims 1-23, wherein at least 55% of the antibody is the main charge variant of the antibody after six months at -80°C.

25. The pharmaceutical formulation of any one of claims 1-24, wherein the percent relative potency of the antibody after six months at -80°C is at least 85% of the potency of the antibody prior to storage.

26. The pharmaceutical formulation of any one of claims 1-25, wherein at least 96% of the antibody has native conformation after six months at -30°C.

27. The pharmaceutical formulation of any one of claims 1-26, wherein at least 55% of the antibody is the main charge variant of the antibody after six months at -30°C.

28. The pharmaceutical formulation of any one of claims 1-27, wherein the percent relative potency of the antibody after six months at -30°C is at least 84% of the potency of the antibody prior to storage.

29. The pharmaceutical formulation of any one of claims 1-28, wherein at least 96% of the antibody has native conformation after six months at -20°C.

30. The pharmaceutical formulation of any one of claims 1-29, wherein at least 55% of the antibody is the main charge variant of the antibody after six months at -20°C.

31. The pharmaceutical formulation of any one of claims 1-30, wherein the percent relative potency of the antibody after six months at -20°C is at least 90% of the potency of the antibody prior to storage.

32. A pharmaceutical formulation comprising (a) 25 mg/mL mL ± 3.75 mg/mL of an anti-Ang-2 antibody, (b) 10 mM ± 1.5 mM histidine, pH 6 ± 0.3, (c) 0.2% w/v ± 0.03% polysorbate 20, and (d) 10% w/v ± 1.5% sucrose, wherein:

(a) the antibody comprises an HCVD of SEQ ID NO: 18 and an LCVD of SEQ ID NO: 20;

(b) over 96% of the antibodies have a molecular weight of 151 kDa ± 1 kDa;

(c) at least 53% of the antibodies have an isoelectric point of about 8.13 ± 0.01; and

(d) from about 90% to about 92% of the antibodies are fucosylated.

33. The pharmaceutical formulation of claim 32 consisting of (a) 25 mg/mL ± 3.75 mg/mL of the antibody, (b) 10 mM ± 3 mM histidine, pH 6 ± 0.3, (c) 0.2% w/v ± 0.03% polysorbate 20, and (d) 10% w/v ± 1.5% sucrose, in water.

34. A pharmaceutical formulation comprising (a) 50 mg/mL mL ± 7.5 mg/mL of an anti-Ang-2 antibody, (b) 10 mM ± 1.5 mM histidine, pH 6 ± 0.3, (c) 0.2% w/v ± 0.03% polysorbate 20, and (d) 10% w/v ± 1.5% sucrose, wherein:

(a) the antibody comprises an HCVD of SEQ ID NO: 18 and an LCVD of SEQ ID NO: 20;

(b) over 96% of the antibodies have a molecular weight of 151 kDa ± 1 kDa;

(c) at least 53% of the antibodies have an isoelectric point of about 8.13 ± 0.01; and

(d) from about 90% to about 92% of the antibodies are fucosylated.

35. The pharmaceutical formulation of claim 34 consisting of (a) 50 mg/mL mL ± 7.5 mg/mL of the antibody, (b) 10 mM ± 1.5 mM histidine, pH 6 ± 0.3, (c) 0.2% w/v ± 0.03% polysorbate 20, and (d) 10% w/v ± 1.5% sucrose, in water.

36. A pharmaceutical composition of any one of claims 1-35, wherein said composition is contained in a container.

37. The pharmaceutical composition of claim 36, wherein the container is a vial.

38. The pharmaceutical composition of claim 37, wherein the vial is glass.

39. The pharmaceutical composition of claim 36, wherein the container is an IV drip bag.

40. The pharmaceutical composition of claim 39, wherein the bag is made of polyvinyl chloride.

41. The pharmaceutical composition of claim 39, wherein the bag is made of polyolefin.

42. A kit comprising a pharmaceutical composition of any one of claims 1-35, a container, and instructions.

43. The kit of claim 42, wherein the container is a glass vial fitted with a FLUROTEC–coated 4023/50 rubber stopper.

What is claimed is:

1. A stable pharmaceutical formulation comprising:

(i) an antibody at a concentration of from 20 ± 3 mg/ml to 60 ± 9 mg/ml that binds specifically to human angiopoietin 2 (human Ang-2), wherein the antibody comprises a heavy chain variable domain (HCVD) having the amino acid sequence of SEQ ID NO:18 and a light chain variable domain (LCVD) having the amino acid sequence of SEQ ID NO:20;

(ii) histidine at a concentration of 10 ± 1.5 mM;

(iii) polysorbate 20 in an amount of 0.2% w/v ± 0.03% w/v; and

(iv) sucrose in an amount of 10% w/v ± 1.5% w/v,

wherein the formulation has a pH of 6 ± 0.3, and at least 92% of the antibody has native conformation when the formulation is kept at about 45°C for up to about 28 days.

2. The pharmaceutical formulation of claim 1, wherein

(a) over 96% of the antibodies have a molecular weight of 151 kDa ± 1 kDa;

(b) at least 53% of the antibodies have an isoelectric point of about 8.13 ± 0.01; and

(c) from about 90% to about 92% of the antibodies are fucosylated.

3. The pharmaceutical formulation of claim 1, wherein the antibody concentration is about 25 mg/mL ± 0.375 mg/mL.

4. The pharmaceutical formulation of claim 1, wherein the antibody concentration is about 50 mg/mL ± 7.5 mg/mL.

5. The pharmaceutical formulation of claim 1, wherein at least 93% of the antibody has native conformation after 28 days at 45°C.

6. The pharmaceutical formulation of claim 1, wherein at least 32% of the antibody is the main charge variant of the antibody after 28 days at 45°C.

7. The pharmaceutical formulation of claim 1, wherein at least 97% of the antibody has native conformation after 28 days at 25°C.

8. The pharmaceutical formulation of claim 1, wherein at least 53% of the antibody is the main charge variant of the antibody after 28 days at 25°C.

9. The pharmaceutical formulation of claim 1, wherein at least 96% of the antibody has native conformation after 28 days at 37°C.

10. The pharmaceutical formulation of claim 1, wherein at least 45% of the antibody is the main charge variant of the antibody after 28 days at 37°C.

11. The pharmaceutical formulation of claim 1, wherein at least 97% of the antibody has native conformation after six months at 5°C.

12. The pharmaceutical formulation of claim 1, wherein at least 55% of the antibody is the main charge variant of the antibody after six months at 5°C.

13. The pharmaceutical formulation of claim 1, wherein the percent relative potency of the antibody after six months at 5°C is at least 100% of the potency of the antibody prior to storage.

14. The pharmaceutical formulation of claim 1, wherein at least 97% of the antibody has native conformation after six months at -80°C.

15. The pharmaceutical formulation of claim 1, wherein at least 55% of the antibody is the main charge variant of the antibody after six months at -80°C.

16. The pharmaceutical formulation of claim 1, wherein the percent relative potency of the antibody after six months at -80°C is at least 85% of the potency of the antibody prior to storage.

17. The pharmaceutical formulation of claim 1, wherein at least 96% of the antibody has native conformation after six months at -30°C.

18. The pharmaceutical formulation of claim 1, wherein at least 55% of the antibody is the main charge variant of the antibody after six months at -30°C.

19. The pharmaceutical formulation of claim 1, wherein the percent relative potency of the antibody after six months at -30°C is at least 84% of the potency of the antibody prior to storage.

20. The pharmaceutical formulation of claim 1, wherein at least 96% of the antibody has native conformation after six months at -20°C.

21. The pharmaceutical formulation of claim 1, wherein at least 55% of the antibody is the main charge variant of the antibody after six months at -20°C.

22. The pharmaceutical formulation of claim 1, wherein the percent relative potency of the antibody after six months at -20°C is at least 90% of the potency of the antibody prior to storage.

23. A pharmaceutical formulation comprising (a) 25 mg/mL ± 3.75 mg/mL of an anti-Ang-2 antibody, (b) 10 mM ± 1.5 mM histidine, pH 6 ± 0.3, (c) 0.2% w/v ± 0.03% polysorbate 20, and (d) 10% w/v ± 1.5% sucrose, wherein:

(a) the antibody comprises an HCVD of SEQ ID NO: 18 and an LCVD of SEQ ID NO: 20;

(b) over 96% of the antibodies have a molecular weight of 151 kDa ± 1 kDa;

(c) at least 53% of the antibodies have an isoelectric point of about 8.13 ± 0.01; and

(d) from about 90% to about 92% of the antibodies are fucosylated.

24. The pharmaceutical formulation of claim 23 consisting of (a) 25 mg/mL ± 3.75 mg/mL of the antibody, (b) 10 mM ± 1.5 mM histidine, pH 6 ± 0.3, (c) 0.2% w/v ± 0.03% polysorbate 20, and (d) 10% w/v ± 1.5% sucrose, in water.

25. A pharmaceutical formulation comprising (a) 50 mg/mL ± 7.5 mg/mL of an anti-Ang-2 antibody, (b) 10 mM ± 1.5 mM histidine, pH 6 ± 0.3, (c) 0.2% w/v ± 0.03% polysorbate 20, and (d) 10% w/v ± 1.5% sucrose, wherein:

(a) the antibody comprises an HCVD of SEQ ID NO: 18 and an LCVD of SEQ ID NO: 20;

(b) over 96% of the antibodies have a molecular weight of 151 kDa ± 1 kDa;

(c) at least 53% of the antibodies have an isoelectric point of about 8.13 ± 0.01; and

(d) from about 90% to about 92% of the antibodies are fucosylated.

26. The pharmaceutical formulation of claim 25 consisting of (a) 50 mg/mL ± 7.5 mg/mL of the antibody, (b) 10 mM ± 1.5 mM histidine, pH 6 ± 0.3, (c) 0.2% w/v ± 0.03% polysorbate 20, and (d) 10% w/v ± 1.5% sucrose, in water.

27. A pharmaceutical composition comprising the formulation of claim 1, wherein said composition is contained in a container.

28. The pharmaceutical composition of claim 27, wherein the container is a vial.

29. The pharmaceutical composition of claim 28, wherein the vial is glass.

30. The pharmaceutical composition of claim 27, wherein the container is an intravenous drip bag.

31. The pharmaceutical composition of claim 30, wherein the bag is made of polyvinyl chloride.

32. The pharmaceutical composition of claim 30, wherein the bag is made of polyolefin.

33. A kit comprising a pharmaceutical composition of claim 27, and instructions.

34. The kit of claim 33, wherein the container is a glass vial fitted with a fluorocarbon coated rubber stopper.